PMID- 22410369
OWN - NLM
STAT- MEDLINE
DCOM- 20120905
LR  - 20220318
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 3
IP  - 3
DP  - 2012 Mar
TI  - Expressions of matrix metalloproteinase-9 (MMP-9), dentin sialophosphoprotein 
      (DSPP), and osteopontin (OPN) at histologically negative surgical margins may 
      predict recurrence of oral squamous cell carcinoma.
PG  - 286-98
AB  - Up to 50% of oral squamous cell carcinomas (OSCCs) recur following surgical 
      resections with conventional "histologically-negative" margins. Three members of 
      the SIBLING family of proteins: dentin sialophophoprotein (DSPP); bone 
      sialoprotein (BSP); and osteopontin OPN are upregulated in OSCCs. In this study, 
      we aimed to correlate the expression of DSPP, OPN and BSP as well as three 
      SIBLING-partners, matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-3 
      (MMP-3), and matrix metalloproteinase-9 (MMP-9), at histologically-negative 
      margins of OSCCs with tumor recurrence. Immunohistochemical analyses of the 
      SIBLINGs and MMP expressions at histologically-negative margins of OSCC was 
      carried out in a retrospective study of 20 patients, and the results correlated 
      with tumor recurrence. Each protein was dichotomized as "present" (>/=10% staining) 
      or "absent" (more than 10% staining). The Sensitivity, Specificity, Positive 
      Predictive Value(PV+) and Negative Predictive Value (PV-) for recurrence was 
      calculated for each protein, along with their overall diagnostic accuracy, 
      calculated as: (number of true positives + number of true negatives)/ number of 
      patients. OSCC recurred in 9 of 20 patients (45%), a ratio not significantly 
      different from the estimated population recurrence rate of 50% (p = 0.664). Among 
      the SIBLINGs, DSPP and OPN showed the greatest Accuracy with DSPP being more 
      Sensitive (89%) and OPN more Specific (64%). MMP-9 showed the greatest overall 
      Accuracy (80%), slightly less Sensitivity (67%) and more Specificity (100%), than 
      either DSPP or OPN. MMP-9 showed a superior positive PV than either DSPP or OPN. 
      The negative PVs of OPN and MMP-9 were almost identical, and inferior to DSPP. We 
      conclude that DSPP, OPN, or MMP-9 expressions at histologically-negative surgical 
      margins predict OSCC recurrence with MMP-9 being the preferred predictor. These 
      proteins may identify patients who could benefit from more extensive resection, 
      or from adjunct treatments such as radiotherapy.
FAU - Ogbureke, Kalu U E
AU  - Ogbureke KU
AD  - College of Dental Medicine, Georgia Health Sciences University, Augusta, GA, USA. 
      kogbureke@georgiahealth.edu
FAU - Weinberger, Paul M
AU  - Weinberger PM
FAU - Looney, Stephen W
AU  - Looney SW
FAU - Li, Li
AU  - Li L
FAU - Fisher, Larry W
AU  - Fisher LW
LA  - eng
GR  - K23 DE017791/DE/NIDCR NIH HHS/United States
GR  - ImNIH/Intramural NIH HHS/United States
GR  - K23DE017791-01A1/DE/NIDCR NIH HHS/United States
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, N.I.H., Intramural
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Extracellular Matrix Proteins)
RN  - 0 (Phosphoproteins)
RN  - 0 (Sialoglycoproteins)
RN  - 0 (dentin sialophosphoprotein)
RN  - 106441-73-0 (Osteopontin)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/metabolism
MH  - Carcinoma, Squamous Cell/*diagnosis/metabolism/pathology/surgery
MH  - Disease-Free Survival
MH  - Extracellular Matrix Proteins/*metabolism
MH  - False Negative Reactions
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Male
MH  - Matrix Metalloproteinase 9/*metabolism
MH  - Middle Aged
MH  - Models, Biological
MH  - Mouth Neoplasms/*diagnosis/metabolism/pathology/surgery
MH  - Neoplasm Recurrence, Local/*diagnosis/metabolism/pathology
MH  - Osteopontin/*metabolism
MH  - Phosphoproteins/*metabolism
MH  - Prognosis
MH  - Retrospective Studies
MH  - Sialoglycoproteins/*metabolism
PMC - PMC3359885
EDAT- 2012/03/14 06:00
MHDA- 2012/09/06 06:00
PMCR- 2012/03/01
CRDT- 2012/03/14 06:00
PHST- 2012/03/14 06:00 [entrez]
PHST- 2012/03/14 06:00 [pubmed]
PHST- 2012/09/06 06:00 [medline]
PHST- 2012/03/01 00:00 [pmc-release]
AID - 373 [pii]
AID - 10.18632/oncotarget.373 [doi]
PST - ppublish
SO  - Oncotarget. 2012 Mar;3(3):286-98. doi: 10.18632/oncotarget.373.